

Application No.: 08/999,752

Docket No.: TEVNHC 3.0-200

[proposed] Examiner's AmendmentRECEIVED
CENTRAL FAX CENTER

Claims 1-45 are canceled.

APR 13 2009

Claim 46 has been amended. In line 7, the phrase "in an amount of 10% w/w to 15% w/w" has been inserted after "ethanol."

Claim 47 has been amended. In line 8, the phrase "in an amount of 10% w/w to 15% w/w" has been inserted after "ethanol."

The following claims (48-65) have been added:

48. The product of claim 46, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

49. The product of claim 46, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

50. The product of claim 46, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

51. The product of claim 46, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

52. The product of claim 47, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

Application No.: 08/999,752

Docket No.: TEVNHC 3.0-200

53. The product of claim 47, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

54. The product of claim 47, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of .88.2% w/w.

55. The product of claim 47, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

56. A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 150 to 250 microns.

57. The product of claim 56, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

58. The product of claim 56, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

Application No.: 08/999,752

Docket No.: TEVNHC 3.0-200

59.. The product of claim 56, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

60. The product of claim 56, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

61. A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists essentially of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein the salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 150 to 250 microns.

62. The product of claim 61, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

63. The product of claim 61, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

64. The product of claim 61, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

Application No.: 08/999,752

Docket No.: TEVNHC 3.0-200

65. The product of claim 61, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.